Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise
Portfolio Pulse from
Gilead Sciences is rated a 'buy' due to its strong HIV business, promising oncology pipeline, and potential for long-term growth. The company reported strong Q3 earnings, with Biktarvy leading in HIV treatments and upgraded 2024 guidance. Liver disease and oncology divisions show potential for growth.
December 29, 2024 | 9:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead Sciences is rated a 'buy' due to its thriving HIV business, promising oncology pipeline, and potential for long-term growth. The company's Q3 earnings show strong performance in HIV treatments, with Biktarvy leading and new regimens expected by 2030, and upgraded 2024 guidance for >$28bn revenues, EPS of >$4.
Gilead's strong performance in its HIV franchise, particularly with Biktarvy, and its promising oncology pipeline contribute to a positive outlook. The upgraded 2024 guidance further supports the 'buy' rating, indicating potential for stock price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100